Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Mourad Nachi"'
Publikováno v:
Journal de la Faculté de Médecine d'Oran, Vol 8, Iss 1 (2024)
Introduction Biochemical exploration of effusion fluids plays a crucial role in the diagnosis of underlying pathologies. This study aimed to evaluate the performance of biochemical ratios and the albumin gradients in the diagnostic process of asci
Externí odkaz:
https://doaj.org/article/9d0acf45a36d48f2b23b6d823b0eb949
Publikováno v:
Journal de la Faculté de Médecine d'Oran, Vol 7, Iss 2, Pp 901-906 (2023)
Background-The high mortality of cirrhosis is a global public health problem. For predicting the outcome of patients with cirrhosis, many prognostic models were proposed.The new Model for End-Stage Liver Disease including serum sodium (MELD-Na) has b
Externí odkaz:
https://doaj.org/article/b86be0f77f254c38b924e8828d083b8d
Publikováno v:
Journal de la Faculté de Médecine d'Oran, Vol 6, Iss 2, Pp 787-794 (2022)
Abstract Background-Diabetes is a real health public problem because of its many potential complications, particularly the cardiovascular ones.The aim of this work was to describe the clinical and biological profile in type 2 diabetic population, the
Externí odkaz:
https://doaj.org/article/6f89676d1bc94c1c86ef60d1951df035
Autor:
Mourad NACHI, Ibtissem KIHEL
Publikováno v:
Journal de la Faculté de Médecine d'Oran, Vol 5, Iss 2 (2021)
In recent years ,scientific and technological oncologie advances had allowed the emergence of a new concept which tends to become a new model in medicine; personalized medicine, capable to analyze the genomic specificities of each individual, to bett
Externí odkaz:
https://doaj.org/article/c41b0aa9919a4323ae52dc7db79c4681
Publikováno v:
Journal de la Faculté de Médecine d'Oran, Vol 4, Iss 1 (2020)
Introduction - The management and long-term outcome of patients affected by chronic myeloid leukemia (CML) hadimproved considerably with the introduction in the 2000’s of tyrosine kinase inhibitors, that revolutionized the prognosis of the disease
Externí odkaz:
https://doaj.org/article/4c50455714974e8ba3e002e9fba43eaa
Autor:
Mourad NACHI, Ibtissem KIHEL, Badra ENTASOLTAN, Karima TAIBI, Djaouad GUELLA, Amine ABED, Yasmine BOUKHATMI, Mohamed-Amine BEKADJA
Publikováno v:
Journal de la Faculté de Médecine d'Oran, Vol 4, Iss 1 (2020)
Aim - In chronic myeloid leukemia (CML), the research of BCR-ABL1 fusion transcript became essential to confirm the molecular diagnosis. In this study, we describe the different types of BCR-ABL1 fusion transcripts found in CML patients in West Alger
Externí odkaz:
https://doaj.org/article/cedd1e85ed044546a0c3044485a563e7
Autor:
Mourad NACHI, Ibtissem KIHEL
Publikováno v:
Journal de la faculté de médecine d Oran. 5
In recent years ,scientific and technological oncologie advances had allowed the emergence of a new concept which tend to become a new model in medicine; personalized medicine, capable to analyze the genomic specificities of each individual, to bette
Autor:
Karima Taibi, Ibtissem Kihel, Amine Abed, djaouad Guella, Badra Enta-Soltane, Yasmine Boukhatmi, Mohamed Amine Bekadja, Mourad Nachi
Publikováno v:
Journal de la Faculté de Médecine d’Oran; Vol. 4 No. 1 (2020); 525-530
Objectif - Dans le contexte de la leucémie myéloïde chronique (LMC), la recherche du transcrit de fusion BCR-ABL1 est devenue indispensable pour confirmer le diagnostic moléculaire. Dans cette étude, nous décrivons les différents types de tran
Autor:
Badra Enta-Soltane, Mourad Nachi, Amine Abed, Ibtissem Kihel, Djaoued Guella, Mohamed Amine Bekadja, Mohamed Brahimi, Nabil Yafour
Publikováno v:
Hematology/oncology and stem cell therapy. 15(2)
Aim In chronic myeloid leukemia (CML), the impact of MBCR-ABL1 major transcript type on disease phenotype and response to treatment still controversial to date. This work aims to study the influence of Mb3a2 and Mb2a2 transcripts on clinico-biologica
Publikováno v:
Journal de la faculté de médecine d'Oran. 4
La prise en charge des patients atteints de leucémie myéloïde chronique a été considérablement améliorée avec l’arrivée dans les années 2000 des inhibiteurs de tyrosine kinase qui ont révolutionné le pronostic de la maladie et ont permi